Identification and validation of plasma protein biomarkers as therapeutic targets in acute myeloid leukemia: an integrative multi-omics study
This study provides the first genetic evidence supporting the causal roles of TNFAIP8, TCL1A, WFDC1, and TNFSF8 in AML, offering new insights for targeted therapy development and biomarker-based disease monitoring.
Authors
- Linhui Hu (ORCID: https://orcid.org/0000-0002-1990-4523)
- Zhimin Zhai (ORCID: https://orcid.org/0000-0002-8989-7808)
- Yangyang Ding (ORCID: https://orcid.org/0000-0003-1588-2571)
- Qingqing Luo (ORCID: https://orcid.org/0000-0002-3401-9135)
- Ya Liao
- Fei Yan (ORCID: https://orcid.org/0000-0003-4750-1200)
Institutions
- Nanchang University (CN)
- Anhui Medical University (CN)
- Jiangxi Provincial People's Hospital (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1659811
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00